{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:12:59Z","timestamp":1784182379414,"version":"3.55.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Tumor necrosis factor-alpha inhibitors (TNFis) are associated with an increased risk of nonmelanoma skin cancer (NMSC). NMSC rates, at baseline, are highest among elderly patients. There are limited data on the use of TNFis in elderly Americans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>This study evaluates trends in use of TNFis among Medicare patients and estimates the NMSC burden attributable to TNFi use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>A retrospective cohort study was performed using Medicare Part B and D public data sets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The number of TNFi beneficiaries increased by 8.0% between 2019 and 2023 and spending increased by 37.5%. Beneficiaries aged 65 years and older accounted for 51.7% of all TNFi claims in 2023 compared with 45.2% in 2019. The most common prescriber specialty was rheumatology (60.5% of claims); dermatology accounted for 6.8% of claims. We estimate that there were up to 5,743 TNFi-associated NMSCs in Medicare patients in 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>The use of TNFis in elderly Medicare beneficiaries increased despite evidence of increased risk of NMSCs. Ongoing TNFi use may contribute to excess cases of NMSC in the Medicare population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000005245","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:00:13Z","timestamp":1784181613000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Increasing Use of Tumor Necrosis Factor-Alpha Inhibitors Among Medicare Beneficiaries Despite Known Increased Risk of Nonmelanoma Skin Cancer"],"prefix":"10.1097","author":[{"given":"Christine","family":"Learned","sequence":"first","affiliation":[{"name":"Department of Dermatology, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Kim","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudora","family":"Lee","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bichchau M.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"R1-20260716","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"R2-20260716","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R3-20260716","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R4-20260716","doi-asserted-by":"crossref","first-page":"i262","DOI":"10.1136\/bmj.i262","article-title":"Rheumatoid arthritis, anti\u2013tumor necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden","volume":"352","author":"Raaschou","year":"2016","journal-title":"BMJ"},{"key":"R5-20260716","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.jaad.2026.02.035","article-title":"Tumor necrosis factor alpha inhibitor therapy is associated with increased long-term risk of nonmelanoma skin cancer and melanoma: a retrospective cohort study","volume":"94","author":"Driscoll","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"R6-20260716","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jaad.2025.05.1401","article-title":"Cutaneous malignancy after biologic therapy for inflammatory disease: an active comparator retrospective cohort study","volume":"93","author":"Lauck","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"R7-20260716","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1038\/s41598-021-94504-x","article-title":"Changes in the use patterns of biologic disease-modifying antirheumatic drugs in patients with rheumatic diseases over the past 13 years","volume":"11","author":"S\u00e1nchez-Piedra","year":"2021","journal-title":"Sci Rep"},{"key":"R8-20260716","doi-asserted-by":"crossref","first-page":"e232941","DOI":"10.1001\/jamahealthforum.2023.2941","article-title":"Spending on and use of clinician-administered drugs in Medicare","volume":"4","author":"Hyland","year":"2023","journal-title":"JAMA Health Forum"},{"key":"R9-20260716","doi-asserted-by":"crossref","first-page":"e2025139","DOI":"10.1001\/jamanetworkopen.2020.25139","article-title":"Use of skin cancer procedures, Medicare reimbursement, and overall expenditures, 2012\u20132017","volume":"3","author":"Puri","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R10-20260716","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-3-030-46227-7_6","article-title":"Epidemiology of skin cancer: update 2019","volume":"1268","author":"Leiter","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"R11-20260716","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.det.2019.02.003","article-title":"Management of skin cancer in the elderly","volume":"37","author":"Renzi","year":"2019","journal-title":"Dermatol Clin"},{"key":"R12-20260716","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R13-20260716","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jaad.2021.03.109","article-title":"United States burden of melanoma and nonmelanoma skin cancer from 1990 to 2019","volume":"85","author":"Aggarwal","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R14-20260716","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jamcollsurg.2006.08.026","article-title":"Surgical risk factors, morbidity, and mortality in elderly patients","volume":"203","author":"Turrentine","year":"2006","journal-title":"J Am Coll Surg"},{"key":"R15-20260716","doi-asserted-by":"crossref","first-page":"103754","DOI":"10.1016\/j.critrevonc.2022.103754","article-title":"Current knowledge of immunosuppression as a risk factor for skin cancer development","volume":"177","author":"Rollan","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"R16-20260716","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/tri.13520","article-title":"Initial skin cancer screening for solid organ transplant recipients in the United States: delphi method development of expert consensus guidelines","volume":"32","author":"Crow","year":"2019","journal-title":"Transpl Int"},{"key":"R17-20260716","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1158\/1055-9965.EPI-21-0125","article-title":"Tumor necrosis factor inhibitors and the risk of cancer among older Americans with rheumatoid arthritis","volume":"30","author":"D'Arcy","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R18-20260716","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.cgh.2024.12.011","article-title":"AGA clinical practice update on noncolorectal cancer screening and vaccinations in patients with inflammatory bowel disease: expert review","volume":"23","author":"Caldera","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R19-20260716","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R20-20260716","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2022.11.043","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R23-20260716","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2008.07.047","article-title":"A relative value unit\u2013based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption","volume":"61","author":"Rogers","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R25-20260716","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3899\/jrheum.201017","article-title":"Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemic","volume":"48","author":"George","year":"2021","journal-title":"J Rheumatol"},{"key":"R26-20260716","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/acr.24744","article-title":"Rapid review of medication taking (adherence) among patients with rheumatic diseases during the COVID-19 pandemic","volume":"74","author":"Rebi\u0107","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R27-20260716","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.semarthrit.2017.03.008","article-title":"Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"47","author":"Cantini","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R28-20260716","doi-asserted-by":"crossref","first-page":"e2542937","DOI":"10.1001\/jamanetworkopen.2025.42937","article-title":"Biologic drug prices in Medicare Part B after entry of biosimilars to the market","volume":"8","author":"Abdelaziz","year":"2025","journal-title":"JAMA Netw Open"},{"key":"R29-20260716","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3899\/jrheum.200310","article-title":"Use of disease-modifying antirheumatic drugs, biologics, and corticosteroids in older patients with rheumatoid arthritis over 20 years","volume":"48","author":"Hanly","year":"2021","journal-title":"J Rheumatol"},{"key":"R31-20260716","doi-asserted-by":"crossref","first-page":"1294416","DOI":"10.3389\/fimmu.2023.1294416","article-title":"Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000005245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:00:17Z","timestamp":1784181617000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000005245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000005245","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}